AMR Centre, Shionogi team up for superbug therapy
The therapy has already produced encouraging results in pre-clinical studies and regulatory toxicology tests in preparation for first-in-human clinical trials.
Read More
Tag: humanised monoclonal antibody
Teva abandons Ajovy trial for cluster headaches
A Phase III study found that the primary endpoint for weekly average number of cluster headache attacks during the four-week treatment period is unlikely to be met.
Read More
EU approves new dosing schedule for MSD’s Keytruda
The less frequent dosing gives both patients and oncologists more flexibility, helping to free up hospitals.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
